January 16, 2026 · Form 4 insider transaction
Uihlein Richard E bought 60,000 shares of Galectin Therapeutics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 5 days after the transaction.
The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.; The options vest 100% on December 31, 2026.